Odyssey Therapeutics (ODTX) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Odyssey Therapeutics (NASDAQ: ODTX):

• 10/12/2026 – Odyssey Therapeutics is now covered by UBS Group AG. They set a “buy” rating and a $27.00 price target on the stock.
• 10/12/2026 – Odyssey Therapeutics was upgraded by UBS Group AG to “strong-buy”.
• 10/8/2026 – Odyssey Therapeutics is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $42.00 price target on the stock.
• 10/8/2026 – Odyssey Therapeutics is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $42.00 price target on the stock.
• 8/27/2026 – Odyssey Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $44.00 price target on the stock.
• 8/27/2026 – Odyssey Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $44.00 price target on the stock.

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.

Odyssey’s research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.